Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial

Infantile haemangioma (IH) is the most common benign tumour of infancy. In RCT (n=69 <age 60 days), there was a significant improvement in lesion colour, but no significant difference between use of timolol and placebo for complete or nearly complete resolution of IH at 24 weeks.

JAMA Dermatology